Journal article
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
- Fasano S Department of Precision Medicine, Section of Rheumatology, University of Campania Luigi Vanvitelli, Naples, Italy serena.fasano@unicampania.it.
- Riccardi A Department of Precision Medicine, Section of Rheumatology, University of Campania Luigi Vanvitelli, Naples, Italy.
- Messiniti V Department of Precision Medicine, Section of Rheumatology, University of Campania Luigi Vanvitelli, Naples, Italy.
- Caramaschi P Department of Rheumatology, University of Verona, Verona, Italy.
- Rosato E Dipartimento di Medicina Traslazionale e di Precisione, Sapienza University of Rome, Roma, Italy.
- Maurer B Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
- Smith V Department of Rheumatology, University Hospital Ghent, Gent, Belgium.
- Siegert E Department of Rheumatology, Charit University Hospital, Berlin, Germany.
- De Langhe E Department of Development and Regeneration, Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium.
- Riccieri V Clinical Medicine and Therapy, Sapienza University of Rome, Rome, Italy.
- Airó P Rheumatology and Clinical Immunology Department, Spedali Civili di Brescia, Brescia, Italy.
- Mihai C Department of Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucarest, Romania.
- Avouac J Department of Rheumatology, Paris Descartes University, Rheumatology A and INSER U1016, Cochin Hospital, Paris, France.
- Zanatta E Dipartimento di Medicina, DIMED, Universita degli Studi di Padova, Padova, Italy.
- Walker UA Department of Rheumatology, Basel University, Basel, Switzerland.
- Iannone F Department of Rheumatology, University of Bari, Bari, Italy.
- García De la Peña Lefebvre P Department of Rheumatology, Ramon y Cajal University Hospital, Madrid, Spain.
- Distler JHW Department of Internal Medicine III, University of Erlangen, Erlangen, Germany.
- Vacca A Chair and Rheumatology Unit, University Clinic AOU Cagliari, Monserrato, Italy.
- Distler O Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
- Kowal-Bielecka O Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
- Allanore Y Department of Rheumatology, Paris Descartes University, Rheumatology A and INSER U1016, Cochin Hospital, Paris, France.
- Valentini G Department of Precision Medicine, Section of Rheumatology, University of Campania Luigi Vanvitelli, Naples, Italy.
- 2019-08-19
Published in:
- Annals of the rheumatic diseases. - 2019
autoimmune diseases
outcomes research
systemic sclerosis
Clinical Trials as Topic
Disease Progression
Europe
Female
Follow-Up Studies
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Prospective Studies
Scleroderma, Systemic
Severity of Illness Index
Time Factors
English
BACKGROUND
The European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group Activity Index (EScSG-AI) in systemic sclerosis (SSc).
OBJECTIVE
To assess the predictive value for short-term disease severity accrual of the EUSTAR-AI, as compared with those of the EScSG-AI and of known adverse prognostic factors.
METHODS
Patients with SSc from the EUSTAR database with a disease duration from the onset of the first non-Raynaud sign/symptom ≤5 years and a baseline visit between 2003 and 2014 were first extracted. To capture the disease activity variations over time, EUSTAR-AI and EScSG-AI adjusted means were calculated. The primary outcome was disease progression defined as a Δ≥1 in the Medsger's severity score and in distinct items at the 2-year follow-up visit. Logistic regression analysis was carried out to identify predictive factors.
RESULTS
549 patients were enrolled. At multivariate analysis, the EUSTAR-AI adjusted mean was the only predictor of any severity accrual and of that of lung and heart, skin and peripheral vascular disease over 2 years.
CONCLUSION
The adjusted mean EUSTAR-AI has the best predictive value for disease progression and development of severe organ involvement over time in SSc.
The European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group Activity Index (EScSG-AI) in systemic sclerosis (SSc).
OBJECTIVE
To assess the predictive value for short-term disease severity accrual of the EUSTAR-AI, as compared with those of the EScSG-AI and of known adverse prognostic factors.
METHODS
Patients with SSc from the EUSTAR database with a disease duration from the onset of the first non-Raynaud sign/symptom ≤5 years and a baseline visit between 2003 and 2014 were first extracted. To capture the disease activity variations over time, EUSTAR-AI and EScSG-AI adjusted means were calculated. The primary outcome was disease progression defined as a Δ≥1 in the Medsger's severity score and in distinct items at the 2-year follow-up visit. Logistic regression analysis was carried out to identify predictive factors.
RESULTS
549 patients were enrolled. At multivariate analysis, the EUSTAR-AI adjusted mean was the only predictor of any severity accrual and of that of lung and heart, skin and peripheral vascular disease over 2 years.
CONCLUSION
The adjusted mean EUSTAR-AI has the best predictive value for disease progression and development of severe organ involvement over time in SSc.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1136/annrheumdis-2019-215787
- PMID 31422354
- Persistent URL
- https://sonar.ch/global/documents/191470
Statistics
Document views: 27
File downloads: